Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Claire J. Coleman"'
Autor:
George R. Stark, Afshin Dowlati, Gary Wildey, Claire J. Coleman, Daniel J. Lindner, Sarmishtha De
Supplementary Fig S1. CBL0137 in combination with cisplatin attenuates SCLC tumor growth. H82 SCLC cells, mixed with Matrigel (1:1), were inoculated subcutaneously into the flanks of NSG mice (n=8). Once the tumors reached â^¼50 mm3, the mice were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cd5bee1b3ca0892a474adad7850c391
https://doi.org/10.1158/0008-5472.22417206.v1
https://doi.org/10.1158/0008-5472.22417206.v1
Autor:
George R. Stark, Afshin Dowlati, Gary Wildey, Claire J. Coleman, Daniel J. Lindner, Sarmishtha De
Supplementary Fig S2. SCLC TICs are enriched for stem cell markers. A, B, C, Expression levels of SOX2, NANOG and OCT4 mRNAs in CD133high and CD133low H82 (A) and H526 (B) cells or CD44high and CD44low H446 (C) cells. D, Levels of SOX2 and OCT4, dete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25641035cf902833a9872d743a1bda6a
https://doi.org/10.1158/0008-5472.22417203
https://doi.org/10.1158/0008-5472.22417203
Autor:
George R. Stark, Afshin Dowlati, Gary Wildey, Claire J. Coleman, Daniel J. Lindner, Sarmishtha De
Supplementary Fig S3. CBL0137 inhibits FACT function in SCLC TICs. A, SSRP1 levels were determined by Western analysis in CD133high or CD133low cells from H82 or H526. β-actin was used as a loading control. B, H82 CD133high cells were treated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a65c53d38298779b9a2c26014d62e0f
https://doi.org/10.1158/0008-5472.22417200.v1
https://doi.org/10.1158/0008-5472.22417200.v1
Autor:
George R. Stark, Afshin Dowlati, Gary Wildey, Claire J. Coleman, Daniel J. Lindner, Sarmishtha De
Traditional treatments of small-cell lung cancer (SCLC) with cisplatin, a standard-of-care therapy, spare the tumor-initiating cells (TIC) that mediate drug resistance. Here we report a novel therapeutic strategy that preferentially targets TICs in S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0be846d6e9f0619530b7d5a499b28974
https://doi.org/10.1158/0008-5472.c.6509775
https://doi.org/10.1158/0008-5472.c.6509775
Autor:
Afshin Dowlati, Sarmishtha De, Daniel J. Lindner, Claire J. Coleman, Gary Wildey, George Stark Stark
Publikováno v:
Cancer Research. 78:2396-2406
Traditional treatments of small-cell lung cancer (SCLC) with cisplatin, a standard-of-care therapy, spare the tumor-initiating cells (TIC) that mediate drug resistance. Here we report a novel therapeutic strategy that preferentially targets TICs in S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c2a87089f12faa79bb18b71dccc8e0d
https://doi.org/10.1158/0008-5472.can-17-1920
https://doi.org/10.1158/0008-5472.can-17-1920
Autor:
Sarmishtha, De, Daniel J, Lindner, Claire J, Coleman, Gary, Wildey, Afshin, Dowlati, George R, Stark
Publikováno v:
Cancer research. 78(9)
Traditional treatments of small-cell lung cancer (SCLC) with cisplatin, a standard-of-care therapy, spare the tumor-initiating cells (TIC) that mediate drug resistance. Here we report a novel therapeutic strategy that preferentially targets TICs in S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c71cf75b6855cac225d4658d0b8b37e1
https://pubmed.ncbi.nlm.nih.gov/29440145
https://pubmed.ncbi.nlm.nih.gov/29440145